Genetic Signatures Ltd
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, a… Read more
Genetic Signatures Ltd - Asset Resilience Ratio
Genetic Signatures Ltd (GSS) has an Asset Resilience Ratio of 57.28% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Genetic Signatures Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Genetic Signatures Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$7.47 Million | 13.68% |
| Short-term Investments | AU$23.82 Million | 43.61% |
| Total Liquid Assets | AU$31.30 Million | 57.28% |
Asset Resilience Insights
- Very High Liquidity: Genetic Signatures Ltd maintains exceptional liquid asset reserves at 57.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Genetic Signatures Ltd Industry Peers by Asset Resilience Ratio
Compare Genetic Signatures Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Genetic Signatures Ltd (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Genetic Signatures Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 43.61% | AU$23.82 Million | AU$54.63 Million | -4.55pp |
| 2024-06-30 | 48.15% | AU$32.40 Million | AU$67.29 Million | +27.78pp |
| 2023-06-30 | 20.38% | AU$10.00 Million | AU$49.08 Million | -21.53pp |
| 2022-06-30 | 41.91% | AU$25.00 Million | AU$59.65 Million | -4.35pp |
| 2021-06-30 | 46.26% | AU$25.00 Million | AU$54.05 Million | +16.08pp |
| 2020-06-30 | 30.17% | AU$15.00 Million | AU$49.72 Million | -21.86pp |
| 2019-06-30 | 52.03% | AU$6.31 Million | AU$12.13 Million | -9.27pp |
| 2018-06-30 | 61.30% | AU$8.95 Million | AU$14.61 Million | -13.34pp |
| 2017-06-30 | 74.64% | AU$13.19 Million | AU$17.67 Million | -- |